Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury

Brain Injury

Volumn 24, Issue 4, 2010, Pages 636-641

  Fridman, Esteban A ^a,b   Krimchansky, Ben Zion ^c   Bonetto, Mariana ^a   Galperin, Tatyana ^c   Gamzu, Elkan R ^d   Leiguarda, Ramon C ^d   Zafonte, Ross ^e  

^a FLENI   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c LOEWENSTEIN REHABILITATION HOSPITAL   (Israel)

^d NeuroHealing Pharmaceuticals Inc (NHPI)   (United States)

^e and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

Author keywords

Apomorphine; Brain injury; Dopaminergic; Minimally conscious state; Vegetative state

Indexed keywords

APOMORPHINE;

ADULT; AGITATION; ARTICLE; BRUXISM; CLINICAL ARTICLE; CONFUSION; CONSCIOUSNESS DISORDER; CONTINUOUS INFUSION; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; EOSINOPHILIA; FEMALE; HALLUCINATION; HUMAN; HYPERSALIVATION; HYPOTENSION; MALE; NAUSEA; PANNICULITIS; PENIS ERECTION; QT PROLONGATION; SIDE EFFECT; SKIN INFLAMMATION; SKIN NODULE; SLEEP DISORDER; SNORING; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VOMITING; YAWNING;

EID: 77949608472     PISSN: 02699052     EISSN: 1362301X     Source Type: Journal    
DOI: 10.3109/02699051003610433     Document Type: Article

References (31)

1. The Multi-Society Task Force Report on Persistent Vegetative State. Medical aspects of the persistent vegetative state. I. New England Journal of Medicine 1994;330: 1499-1508.
2. Giacino JT, et al. The minimally conscious state. Definition and diagnostic criteria. Neurology 2002;58:349-353.
3. Gennarelli TA, Thibault LE, Graham DI. Diffuse axonal injury: An important form of traumatic brain damage. The Neuroscientist 1998;4:202-215.
4. Adams JH, Graham DI, Jennet B. The neuropathology of the vegetative state after an acute brain insult. Brain 2000;123: 1327-1338.
5. Menon DK, Owen AM, et al. Cortical processing in persistent vegetative state. The Lancet 1998;352:200.
6. Laureys S, Faymonville ME, Degueldre C, Del Fiore G, Damas P, Lambermont B, Jannsens N, Aerts J, Franck G, Luxen A, et al. Auditory processing in the vegetative state. Brain 2000;123:1589-1681.
7. Owen AM, Coleman MR, Boly M, Davis MH, Laureys S, Pickard JD. Detecting awareness in the vegetative state. Science 2006;313:1402.
8. Fridman EA, Colvar J, Bonetto M, Gamzu E, Krimchansky BZ, Meli F, Leiguarda RC, Zafonte R. Fast awakening from minimally conscious state with apomorphine. Brain Injury 2009;23:172-177.
9. Donnemiller E, Brenneis C, Wissel J, Scherfler C, Poewe W, Riccabona G, Wenning GK. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: A SPECT study using 123I-beta-CIT and 123I-IBZM. European Journal of Nuclear Medicine 2000;27:1410-1414.
10. Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: Part 1. Journal of Head Trauma Rehabilitation 2000;15:1179-1182.
11. Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: Part 2. Journal of Head Trauma Rehabilitation 2001;16:112-116.
12. Haig AJ, Ruess JM. Recovery from vegetative state of six months' duration associated with Sinemet (levodopa/ carbidopa). Archives of Phis Medical Rehabilitation 1990;71: 1081-1083.
13. Krimchansky B-Z, Sazbon L, Groswasser Z. Differential time and related appearance of signs, indicating improvement in the state of consciousness in vegetative state traumatic brain injury (VS-TBI) patients after initiation of dopamine treatment. Brain Injury 2004;18:1099-1105.
14. Matsuda W, Matsumura A, Komatsu Y, Yanaka K, Nose T. Awakenings from persistent vegetative state: Report of three cases with parkinsonism and brain stem lesions on MRI. Journal of Neurology, Neurosurgery and Psychiatry 2003;74: 1571-1573.
15. Passler M, Riggs R. Positive outcome in traumatic brain injury-vegetative state: Patients treated with bromocriptine. Archives of Physical Medicine Rehabilitation 2001;82: 311-315.
16. Meythaler J, Brunner R, Johnson A, et al. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: A pilot double-blind randomized trial. Journal of Head Trauma Rehabilitation 2002;17:300-313.
17. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clinical Pharmacokinetics 2002;41:261-309.
18. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The 'on-off' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. New England Journal of Medicine 1984;310:483-488.
19. Mawdsley C, Williams IR, Pullar IA, Davidson DL, Kinloch NE. Treatment of parkinsonism by amantadine and levodopa. Clinical and Pharmacological Therapy 1972;13:575-583.
20. Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: A 3 year follow-up. Journal of Neurology, Neurosurgery and Psychiatry 1989;52:773-775.
21. Kolls BJ, Stacy M. Apomorphine: A rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clinical Neuropharmacology 2006;29: 292-301.
22. Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. Movement Disorders 2005;20:151-157.
23. Brogden RN, Carmine AA, Heel RC, et al. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982;24: 360-400.
24. Rappaport M, Hall KM, Hopkins K, Belleza T, Cope DN. Disability rating scale for severe head trauma: Coma to community. Archives of Physical Medicine and Rehabilitation 1982;63:118-123.
25. Rappaport M, Dougherty AM, Kelting BA. Evaluation of coma and vegetative states. Archives of Physical Medicine and Rehabilitation 1992;73:628-634.
26. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: An evidence-based review of its use in Parkinson's disease. Drugs and Aging 2004;21:687-709.
27. Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. Journal of Neurology 2004;251:1370-1374.
28. Apokyn package insert. Physicians' desk reference. Montvale. NJ: Thomson PDR; 2006. pp 2132-2136.
29. Hurst RS, Higdon NR, Lawson JA, et al. Dopamine receptor agonists differ in their actions on cardiac ion channels. European Journal of Pharmacology 2003;482:31-37.
30. Kaplan M, et al. Asymptomatic interval in delayed traumatic intracerebral hemorrhage: Report of two cases. Clinical Neurology and Neurosurgery 2003;105:153-155.
31. Agrawal A, Timothy J, Pandit L, Manju M. Post-traumatic epilepsy: An overview. Clinical Neurology and Neurosurgery 2006;108:433-439.